Advertisement
Table 2 Response to HCV therapy
| Response to HCV therapy | Group A: HCV/HIV co-infected patients | Group B: HCV mono-infected patients | p-values |
|---|---|---|---|
| SVR all, n (%) | 18/36 (50) | 27/52 (52) | 0.860 |
| RVR, n (%) | 9/36 (25) | 17/52 (32) | 0.440 |
| EVR, n (%) | 6/36 (17) | 7/52 (13) | 0.677 |
| SVR GT 1, n (%) | 5/15 (33) | 11/27 (40) | 0.626 |
| SVR GT 2, n (%) | 1/2 (50) | 7/8 (87) | 0.356 |
| SVR GT 3, n (%) | 9/14 (64) | 7/12 (58) | 0.756 |
| SVR GT 4, n (%) | 1/1 (100) | 2/4 (50) | 0.600 |
| GT unknown, n (%) | 2/36 (5) | 0/52 (0) | 0.809 |
| SVR GT 1 + 4, n (%) | 6/16 (37) | 13/31 (41) | 0.770 |
| SVR GT 2 + 3, n (%) | 10/16 (62) | 14/20 (70) | 0.636 |
| Discontinuation of therapy, n (%) | 3/36 (12) | 4/52 (7) | 0.305 |
| Breakthrough infection, n (%) | 1/36 (2) | 0/52 | 0.410 |
| Non-response, n (%) | 5/36 (13) | 3/52 (5) | 0.130 |
| Relapse, n (%) | 7/36 (19) | 9/52 (17) | 0.482 |
| Unknown, n (%) | 2/36 (5) | 9/52 (17) | 0.105 |
| SVR HAART treated patients, n (%) | 14/29 (48) | n.a. | n.a. |
| SVR non-HAART treated patients, n (%) | 4/7 (57) | n.a. | n.a. |
| SVR CD4 Nadir > 200/μl, n (%) | 9/18 (50) | n.a. | n.a. |
| SVR CD4 Nadir < 200/μl, n (%) | 9/18 (50) | n.a. | n.a. |
